Key facts for NCD 210.7
- Benefit category
- Additional Preventive Services
- Effective date
- 04/13/2015
- Implemented 03/07/2016
- Transmittal
- Transmittal 190
- Versions published
- 2
TL;DR
NCD 210.7 sets Medicare's national policy for screening for the human immunodeficiency virus (hiv) infection under the benefit category "Additional Preventive Services", effective 04/13/2015 and implemented 03/07/2016. Effective for claims with dates of service on and after April 13, 2015, CMS has determined that the evidence is adequate to conclude that screening for HIV infection for all individuals between the ages of 15 and 65 years, as recommended with a Grade… It has been revised 1 time since publication and binds every Medicare Administrative Contractor nationally.
Item or service described
A. General
Human Immunodeficiency Virus (HIV) is an infection caused by a retrovirus that affects the immune system. HIV infection causes acquired immune deficiency syndrome (AIDS), a disease which severely compromises an individual’s immune system. It is currently generally accepted that antiretroviral therapy (ART) has significantly reduced HIV-associated morbidity and mortality throughout the world and the United States, and has transformed HIV disease for many, into a chronic, manageable condition. There is also evidence that the use of ART is associated with a substantially decreased risk for transmission of the virus to uninfected persons.
Effective January 1, 2009, the Centers for Medicare & Medicaid Services (CMS) is allowed to add coverage of “additional preventive services” through the national coverage determination (NCD) process if certain statutory requirements are met, as provided in 42 C.F.R. §410.64 (CMS began covering HIV screening effective December 8, 2009). One of those requirements is that the service(s) be categorized as a Grade A (strongly recommends) or Grade B (recommends) rating by the United States Preventive Services Task Force (USPSTF). The USPSTF gives a Grade A recommendation to screening for HIV in:
• All adolescents and adults between the ages of 15 to 65 years,
• Younger adolescents and older adults who are at increased risk of HIV infection, and,
• All pregnant women.
Indications and limitations of coverage
B. Nationally Covered Indications
Effective for claims with dates of service on and after April 13, 2015, CMS has determined that the evidence is adequate to conclude that screening for HIV infection for all individuals between the ages of 15 and 65 years, as recommended with a Grade of A by the USPSTF, is reasonable and necessary for early detection of HIV and is appropriate for individuals entitled to benefits under Part A or enrolled under Part B.
CMS shall cover screening for HIV with the appropriate U.S. Food and Drug Administration (FDA)-approved laboratory tests and point-of-care tests, used consistent with FDA-approved labeling and in compliance with the Clinical Laboratory Improvement Act (CLIA) regulations, when ordered by the beneficiary’s physician or practitioner within the context of a healthcare setting and performed by an eligible Medicare provider for these services, for beneficiaries who meet one of the following conditions:
1. Except for pregnant Medicare beneficiaries addressed below, a maximum of one, annual, voluntary screening for all adolescents and adults between the age of 15 and 65, without regard to perceived risk.
2. Except for pregnant Medicare beneficiaries addressed below, a maximum of one, annual, voluntary screening for adolescents younger than 15 and adults older than 65 who are at increased risk for HIV infection. Increased risk for HIV infection is defined as follows:
Men who have sex with men,
Men and women having unprotected vaginal or anal intercourse,
• Past or present injection drug users,
• Men and women who exchange sex for money or drugs, or have sex partners who do,
• Individuals whose past or present sex partners were HIV-infected, bisexual, or injection drug users,
• Persons who have acquired or request testing for other sexually transmitted infectious diseases,
• Persons with a history of blood transfusions between 1978 and 1985,
• Persons who request an HIV test despite reporting no individual risk factors,
Persons with new sexual partners,
• Persons who, based on individualized physician interview and examination, are deemed to be at increased risk for HIV infection. The determination of “increased risk” for HIV infection is identified by the health care practitioner who assesses the patient’s history, which is part of any complete medical history, typically part of an annual wellness visit and considered in the development of a comprehensive prevention plan. The medical recommendation should be a reflection of the service provided.
3. A maximum of three, voluntary, HIV screenings of pregnant Medicare beneficiaries: (1) when the diagnosis of pregnancy is known, (2) during the third trimester, and, (3) at labor, if ordered by the woman’s clinician.
C. Nationally Non-Covered Indications
Effective for claims with dates of service on and after April 13, 2015:
-Medicare beneficiaries with any known diagnosis of an HIV-related illness are not eligible for this screening test.
-Medicare beneficiaries between the ages of 15 and 65 who have had a prior HIV screening test within 1 year are not eligible for HIV screening (i.e., at least 11 full months must have elapsed following the month in which the previous test was performed in order for the subsequent test to be covered).
-Medicare beneficiaries younger than 15 or older than 65, at increased risk for HIV-related illnesses, who have had a prior HIV screening test within 1 year are not eligible for HIV screening (i.e., at least 11 full months must have elapsed following the month in which the previous test was performed in order for the subsequent test to be covered).
-Pregnant Medicare beneficiaries who have had three specified screening tests within each respective term of pregnancy are not eligible for further HIV screening during their pregnancy.
D. Other
N/A
(This NCD last reviewed April 2015.)
Text reproduced from the CMS Medicare Coverage Database record for NCD 210.7 version 2. View the original on cms.gov.
Local policies that build on this NCD
4 active Local Coverage Determinations cite NCD 210.7 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.
- LCD L39044: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing · Wisconsin Physicians Service Insurance Corporation
- L38988 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing · Palmetto GBA
- L39001 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing · Noridian Healthcare Solutions, LLC
- L39038 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing · CGS Administrators, LLC
How MACs bill NCD 210.7
A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 4 current articles in the Medicare Coverage Database name NCD 210.7, 4 of them with a covered ICD-10-CM list, from 4 contractors. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.
| Contractor | Articles |
|---|---|
| CGS Administrators, LLC | A58747 |
| Noridian Healthcare Solutions, LLC | A58720 |
| Palmetto GBA | A58710 |
| Wisconsin Physicians Service Insurance Corporation | A58761 |
A58710: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
Billing and Coding, effective 2026-08-06 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record
851 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L38988 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.
First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …
A58720: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
Billing and Coding, effective 2026-08-06 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record
851 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L39001 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.
First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …
A58747: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
Billing and Coding, effective 2026-05-14 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record
852 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L39038 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.
First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …
A58761: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
Billing and Coding, effective 2026-08-06 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record
851 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L39044 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.
First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …
Coverage analysis history
CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links 2 analyses to NCD 210.7, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.
- CAG-00409N Screening for the Human Immunodeficiency Virus (HIV) Infection (New, Closed)
- CAG-00409R Screening for the Human Immunodeficiency Virus (HIV) Infection (1st Recon, Closed)
Revision history
08/2017 - Transmittal 3778, dated May 24 2017 is being rescinded and replaced by Transmittal 3835, dated, August 16, 2017 to
remove procedure code 80081 from BR 9980.17 so that the MCSDT screen will mirror the PRVN HIMR screen. All other information
remains the same.
The purpose of this Change Request (CR) is to inform contractors that they shall recognize the specified HCPCS codes for services related
to the Screening for the Human Immunodeficiency Virus (HIV) Infection.
( TN 3835 ) (CR9980)
02/2016 - The purpose of this CR is to inform contractors that CMS has determined that the evidence is adequate to conclude that screening for HIV infection for all individuals between the ages of 15-65 years is reasonable and necessary for early detection of HIV and is appropriate for individuals entitled to benefits under Part A or enrolled in Part B.
Effective date: 04/13/2015. Implementation date: 03/07/2016 ( TN 190 ) (CR9403)
03/2013 - CMS translated the information for this policy from ICD-9-CM/PCS to ICD-10-CM/PCS according to HIPAA standard medical data code set requirements and updated any necessary and related coding infrastructure. These updates do not expand, restrict, or alter existing coverage policy. Implementation date: 10/07/2013 Effective date: 10/1/2015. ( TN 1199 ) ( TN 1199 ) (CR 8197)
02/2011 - Transmittal 118, dated March 23, 2010, is rescinded and replaced with Transmittal 131, dated February 23, 2011, to revise the descriptors of the 3 HIV screening codes to align with the descriptors in the official code files. All other material remains the same. ( TN 131 ) (CR6786)
03/2010 - Transmittal 113, dated February 19, 2010, is rescinded and replaced with Transmittal 118, dated March 23, 2010. Edits have been made to the Business Requirements to provide consistency between the two manuals (Pub. 100-04 and 100-03). See Pub. 100-04, Transmittal 1935, dated March 23, 2010, for further details. All other material remains the same. ( TN 118 ) (CR6786)
02/2010 - Effective Date: 12/08/2009. Implementation Date: 07/06/2010. ( TN 113 ) (CR6786)
How this NCD shows up on remittances
A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.
For teams evaluating QuickIntell software
Evaluate a coverage-review workflow around NCD 210.7
Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — NCD 210.7
What does NCD 210.7 cover?
Effective for claims with dates of service on and after April 13, 2015, CMS has determined that the evidence is adequate to conclude that screening for HIV infection for all individuals between the ages of 15 and 65 years, as recommended with a Grade of A by the USPSTF, is reasonable and necessary for early detection of HIV and is appropriate for individuals entitled to benefits under Part A or enrolled under Part B. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.
When did NCD 210.7 take effect?
The current version (2) is effective 04/13/2015, implemented 03/07/2016, published in transmittal 190. CMS lists 2 versions of this NCD.
Does a Local Coverage Determination override NCD 210.7?
No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database NCDs via the CMS Coverage APIVersion API snapshot 2026-09-27 · effective 2026-09-20 · file national-coverage-ncd.jsonSHA-256 a90fadfd264b9ef4…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- Medicare Coverage Database national coverage analyses (NCA/CAL report) via the CMS Coverage APIVersion API snapshot 2026-11-16 · effective 2026-11-16 · file national-coverage-ncacal.jsonSHA-256 563369a07b95140a…
Disclaimer
This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.